Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Wake up and go to sleep The irony of these two narcolepsy drugs that work to normalise the sleep-wake cycle is that they have to be taken twice per night. Patients have the first dose before they ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Axsome's drug was given a breakthrough designation ... Following after is AXS-12 (reboxetine) for narcolepsy, which could be filed in 2023. In addition to its pipeline candidates, Axsome also ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

The Driver and Vehicle Licensing Agency (DVLA) is warning drivers about various medical conditions that could affect their ability to drive. It urges individuals to declare any listed conditions to ...

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...

However, if you have a medical condition that affects your driving but don't voluntarily give up your licence, you must inform the DVLA, which will decide if you can continue holding a driving licence ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...